Prescient Therapeutics to present latest cancer treatment breakthroughs at world-leading conference
Australian clinical stage oncology company Prescient Therapeutics (ASX: PTX) is set to present the exciting results from...
Australian clinical stage oncology company Prescient Therapeutics (ASX: PTX) is set to present the exciting results from...
Prescient Therapeutics (ASX: PTX) to present Phase 1b cancer trial data at prestigious haematology conference
Prescient Therapeutics (ASX:PTX) has announced that its abstract for the results of a Phase 1b...
Results of a Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) Phase 1b study in T cell lymphomas have been accepted...
Prescient Therapeutics Limited (ASX: PTX) has been witnessing significant achievements and progress towards its goal...
Clinical stage oncology company Prescient Therapeutics (ASX: PTX) has reported a solid end to financial year 2023...
Prescient Therapeutics is on a mission to improve outcomes for cancer patients, and it is...
Steven Yatomi Clarke – CEO and Managing Director – Prescient Therapeutics (ASX:PTX) is a clinical-stage...
Clinical stage oncology company Prescient Therapeutics Ltd (ASX: PTX) has finished off another strong quarter...
It’s the quarterly season again as the ASX market announcements page becomes increasingly flooded with...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.